Title of article :
Predicting responsiveness to sorafenib: can the determination of FGF3/FGF4 amplifications enrich for clinical benefit?
Author/Authors :
harding, james j. memorial sloan kettering cancer center and weill cornell - medical college - department of medicine, New York, USA , abou-alfa, ghassan k. memorial sloan kettering cancer center and weill cornell - medical college - department of medicine, New York, USA
Abstract :
A small proportion of patients with advanced hepatocellular carcinoma harbor FGF3/4 geneamplifications in an 11q13 amplicon. A recent report suggests that the presence of this alteration mightenrich for sensitivity to sorafenib. Further, there is growing evidence that interference with the FGF/FGFRaxis has therapeutic potential in patients with advanced hepatocellular carcinoma.
Keywords :
Hepatocellular carcinoma (HCC) , fibroblast growth factor (FGF) , sorafenib , brivanib , targetedtherapy
Journal title :
Hepatobiliary Surgery and Nutrition
Journal title :
Hepatobiliary Surgery and Nutrition
